




STATE MEDICAID P&T COMMITTEE MEETING  
THURSDAY, February 21, 2012  
7:00 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 114



## MINUTES

**Committee Members Present:**

Ellie Brownstein, M.D.  
Lisa Hunt, R.Ph.  
Roger Martenau, M.D.

Kort Delost, R.Ph.  
Julia Ozbolt, M.D.

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, Pharm.D.  
Richard Sorenson, R.N.

Bobbi Hansen, CPhT.  
Tim Morley, R.Ph.

**University of Utah Drug Information Center Staff Present:**

Melissa Archer, Pharm.D.

**Other Individuals Present:**

Scott Clegg, Lilly  
Linda Craig, AstraZeneca  
Bert Jones, GlaxoSmithKline  
Paul Bonham, Novo Nordisk

Charissa Anne, J&J  
Scott Larson, BMS  
Laura Lotzenberger, Janssen

Meeting conducted by: Ellie Brownstein.

---

- 1 Review and Approval of December Minutes: Kort Delost made a motion to approve the minutes. Ellie Brownstein seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: Lisa Hunt reported that the majority of PDL the contracts are back and now circulating for State signatures. She also reported that the PDL on the web is being reformatted to include hyperlinks to pertinent information (quantity limits, prior authorizations, program limitations, etc.).
- 3 Drug Utilization Review (DUR) Board update: No update, Robyn Seely is attending national DUR conference.
- 4 **Otic Agents (antibiotics, corticosteroids and combination agents)** – Melissa Archer provided a clinical overview of each of the otic agents being discussed. Based off clinical safety and efficacy the recommendations of the University of Utah College of Pharmacy are to include (as preferred on PDL) at least one otic antibiotic and one (antibiotic/corticosteroid) combination product, based off current utilization.

Lisa Hunt reported how the other states in the Sovereign States Drug Consortium are currently covering otic agents.

There was some discussion regarding the use of ophthalmic agents to treat otic conditions. Ophthalmic agents are already included in the PDL and were not up for discussion at this meeting.

Kort Delost asked if DermOtic should be separated, based off the different indications it carries. There did not appear to be much utilization. Ellie Brownstein suggested approving CiproDex, based solely off utilization.

Public Comment: none.

Board Actions: Ellie Brownstein made a motion that the agents presented appear to be equally safe and efficacious. Roger Martenau seconded the motion. The motion was approved unanimously.

Kort Delost made a motion to approve or make preferred the use of DermOtic for its indicated use. Ellie Brownstein seconded the motion. The motion was approved unanimously.

Kort Delost made a motion, based off marketplace availability, that ofloxacin is included as an otic antibiotic. Ellie Brownstein seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion to include at least one combination product and that the approved combination products must include CiproDex. Julia Ozbolt seconded the motion. The motion was approved unanimously.

Next Meeting Set for Thursday, March 21, 2013 – Multiple Sclerosis Agents  
Meeting Adjourned.  
Minutes prepared by Bobbi Hansen.